Continental Investors Services Inc. Takes $214,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Continental Investors Services Inc. bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,392 shares of the biopharmaceutical company’s stock, valued at approximately $214,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. JFS Wealth Advisors LLC raised its position in Gilead Sciences by 68.1% in the third quarter. JFS Wealth Advisors LLC now owns 400 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 162 shares during the period. Pacifica Partners Inc. lifted its position in Gilead Sciences by 179.7% during the 3rd quarter. Pacifica Partners Inc. now owns 414 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 266 shares in the last quarter. Horan Securities Inc. boosted its holdings in Gilead Sciences by 217.9% in the 3rd quarter. Horan Securities Inc. now owns 461 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 316 shares during the period. Capital Advisors Ltd. LLC grew its position in Gilead Sciences by 29.4% in the third quarter. Capital Advisors Ltd. LLC now owns 607 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 138 shares in the last quarter. Finally, Wagner Wealth Management LLC purchased a new stake in shares of Gilead Sciences during the second quarter valued at approximately $42,000. Institutional investors and hedge funds own 78.72% of the company’s stock.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 12,984 shares of the firm’s stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $79.96, for a total transaction of $1,038,200.64. Following the transaction, the insider now directly owns 70,130 shares of the company’s stock, valued at $5,607,594.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research firms recently weighed in on GILD. Morgan Stanley raised their price target on shares of Gilead Sciences from $80.00 to $81.00 and gave the company an “equal weight” rating in a report on Friday, February 3rd. Piper Sandler lifted their target price on Gilead Sciences from $111.00 to $112.00 and gave the stock an “overweight” rating in a research report on Friday, February 3rd. Barclays increased their price target on Gilead Sciences from $76.00 to $84.00 and gave the company an “equal weight” rating in a report on Wednesday, January 18th. Bank of America restated a “neutral” rating and set a $85.00 price objective on shares of Gilead Sciences in a report on Tuesday, December 13th. Finally, Royal Bank of Canada reduced their target price on Gilead Sciences from $87.00 to $86.00 and set a “sector perform” rating for the company in a research note on Monday, March 6th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $89.40.

Gilead Sciences Stock Performance

GILD stock opened at $77.31 on Friday. Gilead Sciences, Inc. has a 1 year low of $57.17 and a 1 year high of $89.74. The stock has a market capitalization of $96.41 billion, a price-to-earnings ratio of 21.18, a PEG ratio of 0.95 and a beta of 0.38. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.15 and a current ratio of 1.29. The stock’s fifty day moving average is $83.20 and its two-hundred day moving average is $78.51.

Gilead Sciences (NASDAQ:GILD – Get Rating) last posted its earnings results on Thursday, February 2nd. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.50 by $0.17. Gilead Sciences had a net margin of 16.83% and a return on equity of 44.46%. The firm had revenue of $7.39 billion during the quarter, compared to analyst estimates of $6.63 billion. During the same period in the previous year, the business posted $0.69 EPS. Gilead Sciences’s revenue was up 2.0% on a year-over-year basis. On average, research analysts predict that Gilead Sciences, Inc. will post 6.84 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 30th. Investors of record on Wednesday, March 15th will be given a $0.75 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.73. This represents a $3.00 annualized dividend and a yield of 3.88%. The ex-dividend date is Tuesday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 82.19%.

About Gilead Sciences

(Get Rating)

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.